Valid for Submission
Z16.33 is a billable diagnosis code used to specify a medical diagnosis of resistance to antiviral drug(s). The code Z16.33 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
The ICD-10-CM code Z16.33 might also be used to specify conditions or terms like amantadine resistant virus present, drug resistance, drug resistance, drug resistance to antiretroviral therapy, drug resistance to antiviral agent , infection due to resistant virus, etc.
The code Z16.33 describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
Index to Diseases and Injuries
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code Z16.33 are found in the index:
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Amantadine resistant virus present
- Drug resistance
- Drug resistance
- Drug resistance to antiretroviral therapy
- Drug resistance to antiviral agent
- Infection due to resistant virus
- Oseltamivir resistant virus present
- Zanamivir resistant virus present
Diagnostic Related Groups - MS-DRG Mapping
Convert Z16.33 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code Z16.33 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.